$NOVN News

Last published 3mo ago

3mo agoNOVN NOVNQPelthos Therapeutics Second Quarter Fiscal 2026 Financial Results Conference Call - NOVAN INCEarnings Call TranscriptsGreetings, and welcome to the Q2 2026 Pelthos Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone requires
3y agoLGND NOVNLigand Offers $15 Million to Acquire Assets of Novan, Inc.Business WireLigand provides bridge and debtor-in-possession ("DIP") financing to Novan Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has made an offer to acquire the assets of Novan, Inc.
3y agoLGND NOVNNovan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionGlobeNewswire– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in
3y agoNOVNNovan to Provide Corporate Update at its 2023 Annual Meeting of StockholdersGlobeNewswireDURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will host a live audio webcast of the Company's 2023 Annual Meeting of Stockholders ("ASM")
3y agoNOVNNovan Focuses Strategic Direction and Announces RestructuringGlobeNewswire– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction
3y agoNOVNNovan, Inc. (NOVN) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoNOVNNovan Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m.
3y agoNOVNNovan to Report First Quarter 2023 Financial Results on May 15, 2023GlobeNewswireDURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management
3y agoANEB LGND NOVN NVS+2Ligand Reports First Quarter 2023 Financial ResultsBusiness Wire2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and
3y agoNOVNNovan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹GlobeNewswirePublished results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight impact on patient adherence of early onset of improvement with topical
3y agoNOVNNovan to Host Analyst and Investor Event: A Discussion of Molluscum's Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDGlobeNewswireDURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum's Unmet Need with
3y agoNOVNNovan (NOVN) Q4 2022 Earnings Call TranscriptEarnings Call Transcripts
3y agoNOVNNovan Reports Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswire– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted products, RHOFADE, WYNZORA and MINOLIRA – – Company to host conference
3y agoNOVNNovan to Report Full Year 2022 Financial Results on March 30, 2023GlobeNewswireDURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan
3y agoNOVNNovan Announces Closing of $6.0 Million Registered Direct OfferingGlobeNewswireDURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the closing of the issuance and sale in the Company's previously announced registered direct
3y agoNOVNNovan to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireDURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the
3y agoNOVNNovan Announces $6.0 Million Registered Direct OfferingGlobeNewswireDURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a registered direct
3y agoNOVNNovan Moves Forward with Unified Corporate BrandingGlobeNewswire– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified identity in advance of
3y agoNOVNFDA Accepts Novan's NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024GlobeNewswire– FDA completes filing review of application with no filing issues identified – – New Chemical Entity ("NCE") has potential to be the first FDA-approved prescription product for molluscum in the U.S. – – Novan's
3y agoNOVNNovan to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewswireDURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the
3y agoLGND NOVNLigand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum ContagiosumBusiness WirePotential FDA approval anticipated in the first quarter of 2024, assuming FDA filing acceptance and standard review timelines Molluscum contagiosum is a viral skin infection that affects approximately 6 million people,
3y agoNOVNNovan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum ContagiosumGlobeNewswire– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that affects approximately 6
3y agoNOVNEPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in JapanGlobeNewswireDURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive
3y agoHTBK NOVNEPI Health, a Novan Company, Executes a $15.0 Million Financing AgreementGlobeNewswire– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) --
3y agoNOVNNovan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech ConferenceGlobeNewswire– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) --
3y agoNOVNNovan Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of
4y agoNOVNNovan to Report Third Quarter 2022 Financial Results on November 14, 2022GlobeNewswireDURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14th. Novan
4y agoNOVNEPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA's® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®GlobeNewswireDURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced positive data
4y agoNOVNEPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®GlobeNewswireDURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that data from a
4y agoNOVNNovan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®GlobeNewswireDURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for poster presentation at
4y agoNOVNEPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 ConferenceGlobeNewswire– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis DURHAM, N.C. and COPENHAGEN, Denmark, Sept.
4y agoNOVNNovan Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the end of 2022 – – Company to host c
4y agoNOVNNovan to Report Second Quarter 2022 Financial Results on August 11, 2022GlobeNewswireDURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th. Novan management will host a conference call a
4y agoNOVNNovan Satisfies $16.5 Million Outstanding Promissory NoteGlobeNewswire– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations – – Novan saves $11.1 million in principal and future interest payments with this agreement –
4y agoNOVNNovan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA DermatologyPR Newswire– The B-SIMPLE4 pivotal Phase 3 clinical study of berdazimer gel, 10.3% (SB206) is the largest interventional trial of molluscum contagiosum ("molluscum") (n=891)1 – – Company previously reported positive topline efficacy and favorable safety dat
4y agoNOVNNovan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewswireDURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the closing of the Company's previously announced registered direct offering priced at-the-market under Nasdaq rules with an instituti
4y agoNOVNNovan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewswireDURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced it has entered into a definitive agreement with an institutional investor to sell to the investor, in a registered direct offering pri
4y agoNOVNNovan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative DermatologyGlobeNewswire– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum –
4y agoNOVNNovan Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward submission of first New Drug Application (NDA) f
4y agoNOVNNovan to Report First Quarter 2022 Financial Results on May 16, 2022GlobeNewswireDURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th. Novan management will host a conference call and live
4y agoNOVNNovan to Participate in the Virtual Investor Innovation in Dermatology Spotlight EventGlobeNewswireDURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology Spotlight event on Tuesday, April 26, 2022, at 2:00 PM ET. F
4y agoNOVNNovan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology's (AAD) 2022 Annual MeetingGlobeNewswireDURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum was selected for
4y agoNOVNNovan, Inc. to Present at Two Upcoming Investor ConferencesGlobeNewswireDURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will be presenting at two upcoming investor conferences.
4y agoNOVNEVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INCPR NewswireCHARLESTON, S.C., March 11, 2022 /PRNewswire/ -- Evening Post Group ("EPG"), a family-owned operating group based in Charleston, South Carolina, is excited to announce the successful sale of EPI Health, LLC to Novan, Inc (NASDAQ:NOVN), a public specialty
4y agoNOVNEPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology CompanyACCESS NewswireResulting entity to have broad portfolio of commercial product in dermatology and established pipeline of early and late-stage product candidates in development across multiple indications Company to host conference call and webcast today at 8:30 E.T.
4y agoNOVNNovan Acquires EPI Health, a Specialty Dermatology CompanyGlobeNewswire– EPI Health promotes four prescription products posting 2021 operating revenue of $17.6 million – – Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulato
4y agoNOVNNovan Reports Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswire– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline assets SB019, for the treatment of SARS-CoV-2,
4y agoNOVNNovan to Report Full Year 2021 Financial Results on February 22, 2022GlobeNewswireDURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd. Novan management will host a conference call and l
4y agoNOVNNovan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology ConferenceGlobeNewswireDURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that data from the Company's completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206)
5y agoNOVNNovan to Participate in the Virtual Investor Roundtable EventGlobeNewswire– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN),